Article
Medicine, Research & Experimental
Guojuan Miao, Xiuhong Sun
Summary: An immunomodulatory antibody targeting B7-H4 was successfully generated, showing inhibitory activity on T cell immune suppression and ADCC activity in B7-H4-positive tumors. This antibody could potentially serve as a promising immunotherapy for B7-H4-expressing tumors.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Multidisciplinary Sciences
Resmi Ravindran, Cindy McReynolds, Jun Yang, Bruce D. Hammock, Aamer Ikram, Amna Ali, Adnan Bashir, Tanzeel Zohra, W. L. William Chang, Dennis J. Hartigan-O'Connor, Hooman H. Rashidi, Imran H. Khan
Summary: A COVID-19 serological test with high sensitivity and specificity has been developed, measuring antibodies against various coronaviruses. Elevated levels of inflammatory cytokines/chemokines, particularly CXCL-10, were found in many COVID-19 patients. Anti-N antibodies appeared before S-RBD and may differentiate between vaccinated and infected individuals, which is important for current and future S protein-based vaccines.
Article
Medicine, Research & Experimental
Xiaoping Gao, Ting Ye, Yu Lei, Qi Zhang, Yuanning Luo, Haiyan Yang, Xiaochun Zeng, Wen Zhou, Qinglian Wen, Jingbo Liu, Hong Xiong, Runlan Wan
Summary: This study found that Dendrobium officinale aqueous extract (DoAE) can enhance immune response and promote antibody production during COVID-19 vaccination. It also has potential for COVID-19 prophylaxis, treatment, and recovery through its immunomodulatory and anti-inflammatory properties. However, it may affect the production of neutralizing antibodies and thus, not recommended for consumption during COVID-19 vaccination.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Rheumatology
Roy M. Fleischmann, Ricardo Blanco, Stephen Hall, Glen T. D. Thomson, Filip E. Van den Bosch, Cristiano Zerbini, Louis Bessette, Jeffrey Enejosa, Yihan Li, Yanna Song, Ryan DeMasi, In-Ho Song
Summary: The study evaluated the efficacy and safety of immediate switch from upadacitinib to adalimumab, or vice versa, in patients with rheumatoid arthritis who did not respond adequately to initial therapy. Patients who were switched to an alternate therapy based on a treat-to-target strategy showed improvements in disease activity without new safety concerns. Overall, immediate switch without washout between these two therapies was found to be beneficial for patients who were non-responders or incomplete-responders.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Gastroenterology & Hepatology
Xavier Roblin, Capucine Genin, Stephane Nancey, Nicolas Williet, Pauline Veyrard, Gilles Boschetti, Jean-Marc Phelip, Anne-Emmanuelle Berger, Martin Killian, Louis Waeckel, Bernard Flourie, Stephane Paul
Summary: This study compared the efficacy of optimizing adalimumab (ADA) dose and switching to vedolizumab or ustekinumab in patients with inflammatory bowel disease (IBD) who experienced a loss of response despite therapeutic trough levels of ADA. The results showed that in the optimization group, a higher proportion of patients discontinued treatment compared to the swap group, and the time without therapeutic discontinuation was longer in the swap group. Factors associated with treatment discontinuation varied between the two groups.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Infectious Diseases
Thomas Perkmann, Nicole Perkmann-Nagele, Patrick Mucher, Astrid Radakovics, Manuela Repl, Thomas Koller, Galateja Jordakieva, Oswald F. Wagner, Christoph J. Binder, Helmuth Haslacher
Summary: The study suggests that antibody levels quantified before the booster shot with the Roche Elecsys SARS-CoV-2 S assay may predict post-booster responses to BNT162b2, but not to AZD1222. There is a vaccine-dependent effect on antibody responses, with age playing an ambivalent role in the immune response.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Tomoko Hamaya, Shingo Hatakeyama, Tohru Yoneyama, Yuki Tobisawa, Hirotake Kodama, Takeshi Fujita, Reiichi Murakami, Kazuyuki Mori, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Hisao Saitoh, Shunji Narumi, Hirofumi Tomita, Chikara Ohyama
Summary: This study aimed to evaluate the humoral response of ABO blood type incompatible kidney transplant recipients treated with rituximab after the second and third doses of SARS-CoV-2 mRNA vaccine. The results showed that the antibody titer significantly increased after the third dose, leading to an increased seropositivity rate. ABO incompatibility or rituximab use was not significantly associated with seropositivity.
SCIENTIFIC REPORTS
(2023)
Article
Instruments & Instrumentation
Adam A. Walters, Abrar Ali, Julie Tzu-Wen Wang, Khuloud T. Al-Jamal
Summary: This study aimed to investigate the effects of intratumoral injection of immunoadjuvants on antibody response and the ability of serum obtained from in situ vaccinated mice to neutralize circulating tumor cells. The results showed that in situ vaccination can modify the isotype of anti-tumor antibodies, but it is not sufficient to neutralize circulating cancer cells.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2023)
Article
Immunology
Massimo Pieri, Eleonora Nicolai, Marco Ciotti, Marzia Nuccetelli, Serena Sarubbi, Martina Pelagalli, Sergio Bernardini
Summary: This study monitored workers during their vaccination program and found varying levels of antibodies produced after two doses of the vaccine. Individuals with previous natural infection had higher levels of antibodies. Among individuals with no history of infection, some had antibody levels similar to infected individuals, suggesting asymptomatic infection. For such individuals, a single dose of the vaccine may be sufficient to generate a protective immune response.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Benjamin J. Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D. Weiss, Michelle Choe, Jennifer H. Foster, Navin Pinto, Daniel A. Morgenstern, Margarida Simao Rafael, Keri A. Streby, Rachel N. Zeno, Rajen Mody, Sahr Yazdani, Ami Desai, Margaret E. Macy, Suzanne Shusterman, Sara M. Federico, Rochelle Bagatell
Summary: This study focuses on the timing, duration, and evolution of response after I/T/DIN/GM-CSF therapy in children with relapsed HRNB. It found that approximately half of the patients had objective responses, with a substantial improvement in patients with MR/PR on initial evaluation. The treatment was associated with extended PFS in responders both during and after discontinuation.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Immunology
Kieran Walker, Anoop Mistry, Christopher M. Watson, Fatima Nadat, Eleanor O'Callaghan, Matthew Care, Laura A. Crinnion, Gururaj Arumugakani, David T. Bonthron, Clive Carter, Gina M. Doody, Sinisa Savic
Summary: CD19 is involved in the initial activation of B cells and the generation of memory B cells, but its role in the later stages of B cell differentiation is unclear. This study found that CD19 is not necessary for plasma cell generation and their response to CXCL12, but it may affect the response to other ligands that require CD19, potentially affecting cell localization, proliferation, or survival. Therefore, the observed hypogammaglobulinemia in CD19-deficient individuals is likely due to the absence of memory B cells.
JOURNAL OF CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
Yves Michiels, Nadhira Houhou-Fidouh, Gilles Collin, Jerome Berger, Evelyne Kohli
Summary: Patients with rheumatoid arthritis (RA) may have weakened immune responses to the mRNA-1273 SARS-CoV-2 vaccine when treated with low-dose combination therapy of methotrexate and adalimumab, especially in elderly patients.
Review
Gastroenterology & Hepatology
Edo H. J. Savelkoul, Pepijn W. A. Thomas, Lauranne A. A. P. Derikx, Nathan den Broeder, Tessa E. H. Romkens, Frank Hoentjen
Summary: Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, with an annual rate of 10% for infliximab and 13% for adalimumab. Dose escalation rates were higher than loss of response, with 72% and 52% regaining clinical benefit for infliximab and adalimumab, respectively. Uniform definitions are needed for more robust evaluations.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Ophthalmology
Laura E. M. Eurelings, Tom O. A. R. Missotten, Mirjame. J. Van Velthoven, Paul L. A. Van Daele, Jan A. M. Van Laar, P. Martin van Hagen, Alberta A. H. J. Thiadens, Saskia M. Rombach
Summary: This retrospective clinical cohort study evaluated the effectiveness of adalimumab in treating noninfectious uveitis, with an acceptable side effect profile. Most patients achieved inactive disease or remission after discontinuation of adalimumab.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Gastroenterology & Hepatology
Alexa N. Sasson, Ashwin N. Ananthakrishnan
Summary: This study suggests that patients with high titers of anti-drug antibodies to infliximab are as likely to respond to adalimumab therapy as those with low titers, indicating that high titers of antibodies are not predictive of treatment failure.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Offir Ukashi, Barak Pflantzer, Yiftach Barash, Eyal Klang, Shlomo Segev, David J. Ozeri, Ido Veisman, Adi Lahat, Ido Laish, Uri Kopylov, Amit Oppenheim
Summary: The association between diverticular disease and atherosclerotic cardiovascular disease (ASCVD) has been demonstrated previously, mainly in symptomatic subjects. This study aimed to evaluate 10 years cardiovascular risk, exercise performance, and association to ASCVD among subjects with asymptomatic diverticulosis. The results showed that the ASCVD score was higher among subjects with asymptomatic diverticulosis compared to those without diverticulosis. Improved exercise performance was associated with a decreased probability for diverticular disease in screening colonoscopy.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie
Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Moran Livne-Margolin, Daniel Ling, Shani Attia-Konyo, Chaya Mushka Abitbol, Ola Haj-Natour, Bella Ungar, Shomron Ben-Horin, Uri Kopylov
Summary: This study compared the effectiveness of vedolizumab and ustekinumab in treating extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) patients, and found no significant difference between the two in terms of EIM treatment.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Mathurin Fumery, Stephane Nancey, Jerome Filippi, Romain Altwegg, Xavier Hebuterne, Gilles Boshetti, Mathilde Barraud, Jonathan Meynier, Stephane Paul, Xavier Roblin
Summary: This study evaluated the effectiveness and safety of golimumab intensification and identified the best threshold of serum golimumab before drug intensification. The results showed that after golimumab intensification, 40% of patients experienced clinical response, 10% experienced clinical remission, 33% experienced endoscopic response, and 23% experienced endoscopic remission.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Microbiology
Beatriz Miguelena Chamorro, Karelle De Luca, Gokul Swaminathan, Stephanie Longet, Egbert Mundt, Stephane Paul
Summary: Bordetella pertussis and Bordetella bronchiseptica are responsible for whooping cough in humans and chronic cough in dogs, respectively. Both can evade host immune responses, but this ability is more pronounced in B. bronchiseptica. Collaborative efforts between veterinary and human medical fields are essential to control these infections.
CLINICAL MICROBIOLOGY REVIEWS
(2023)
Article
Public, Environmental & Occupational Health
Hadar Mudrik-Zohar, Michal Chowers, Elizabeth Temkin, Pnina Shitrit
Summary: This study found that detailed department-level investigations of nosocomial bloodstream infections (NBSIs) performed by healthcare providers, along with increased staff awareness and frontline ownership, were associated with a significant decrease in NBSI rates hospitalwide.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Asaf Levartovsky, Ido Cohen, Chaya Mushka Abitbol, Miri Yavzori, Ella Fudim, Orit Picard, Uri Kopylov, Shomron Ben-Horin, Bella Ungar
Summary: This retrospective study found that vedolizumab trough levels do not predict response to subsequent medical therapy in patients with inflammatory bowel disease. However, lower drug levels may indicate a more severe disease pattern and potential need for surgery in the future.
Article
Biochemistry & Molecular Biology
Tristan Gabriel-Segard, Jessica Rontard, Louise Miny, Louise Dubuisson, Aurelie Batut, Delphine Debis, Melanie Gleyzes, Fabien Francois, Florian Larramendy, Alessandra Soriano, Thibault Honegger, Stephane Paul
Summary: This study presents a microfluidic technology that models bilateral neuro-immunological communication, confirming the communication between dendritic cells and neurons in inflammatory conditions such as IBD. The platform can be used for pharmacological compound screening and may help improve patient outcomes by blocking the gut-brain axis at a mucosal level.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Gastroenterology & Hepatology
Xavier Roblin, Stephane Paul
JOURNAL OF CROHNS & COLITIS
(2023)
Editorial Material
Veterinary Sciences
Beatriz Miguelena Chamorro, Gokul Swaminathan, Egbert Mundt, Stephane Paul
Summary: Oral vaccines are convenient to administer and can activate mucosal immune responses. However, preclinical studies using gavage as a technique for oral vaccine administration have limitations. Alternative methods need to be explored.
Article
Gastroenterology & Hepatology
Stav Dan, Bella Ungar, Shani Ben-Moshe, Keren Bahar Halpern, Miri Yavzori, Ella Fudim, Orit Picard, Chaya Mushka Abitbol, Sivan Harnik, Iris Barshack, Uri Kopylov, Shomron Ben-Horin, Shalev Itzkovitz
Summary: Noninvasive methods for evaluating inflammation in Crohn's disease and ulcerative colitis patients are needed. Fecal wash host shed-cell transcriptomics has shown potential for classifying inflammation in inflammatory bowel disease patients, but its applicability to proximal intestinal segments is currently unknown.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Raizy Kellerman, Amit Bleiweiss, Shimrit Samuel, Reuma Margalit-Yehuda, Estelle Aflalo, Oranit Barzilay, Shomron Ben-Horin, Rami Eliakim, Eyal Zimlichman, Shelly Soffer, Eyal Klang, Uri Kopylov
Summary: This study aimed to develop a deep learning model to predict the need for biological therapy in newly-diagnosed Crohn's disease (CD) patients. The results showed that the model achieved high accuracy in predicting the need for biological therapy in CD patients.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Uria Shani, Eyal Klang, Simon Lassman, Bella Ungar, Shomron Ben-Horin, Uri Kopylov
Summary: This study aimed to describe the outcome of IBD patients with prior malignancy. It found that the use of anti-TNF agents for IBD treatment may increase the risk of NMSC recurrence. Therefore, rigorous dermatological follow-up is important for IBD patients with previous NMSC treated with anti-TNFs.
ANNALS OF GASTROENTEROLOGY
(2023)
Review
Medicine, General & Internal
Mathilde Barrau, Xavier Roblin, Leslie Andromaque, Aurore Rozieres, Mathias Faure, Stephane Paul, Stephane Nancey
Summary: Data on the long-term effects of in utero drug exposure on childhood development are lacking, but therapeutic drug monitoring during pregnancy can help limit fetal drug exposure. The levels and duration of drug exposure impact the outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Xavier Roblin, Stephane Nancey, Konstantinos Papamichael, Gerard Duru, Mathurin Flamand, Sandy Kwiatek, Adam Cheifetz, Nicole Fabien, Mathilde Barrau, Stephane Paul
Summary: Higher concentrations of subcutaneous infliximab are associated with better therapeutic outcomes in patients with inflammatory bowel disease, especially deep remission.
JOURNAL OF CROHNS & COLITIS
(2023)